0.1610USD+4.34%Mkt Cap: —P/E: —1d ago
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value56.79M $
Revenue (TTM)34.56M $
Gross Profit-78.68M $
Net Income (TTM)-123.33M $
Revenue/Share0.1070 USD
Last Price0.1610 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees142
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS8006771062
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.53
EV/Revenue1.64
P/S—
P/B-3.43
EPS (TTM)-1.21
EPS (Forward)—
52W Range
0.151171% of range0.1650
52W High0.1650 USD
52W Low0.1511 USD
Profitability
Gross Margin-227.67%
Oper. Margin-2215.39%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-94.37%
Growth
Revenue Growth-77.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-90.34M $
CapEx (TTM)—
FCF Margin-140.57%
FCF Yield—
Net Debt-8.25M $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity—
Current Ratio0.70
Quick Ratio0.64
Book Value/Sh-0.0460 USD
Cash/Share0.0670 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.102.09M
Float410.44M
Insiders0.93%
Institutions9.60%
Technical
SMA 500.7206 (-77.7%)
SMA 2000.8090 (-80.1%)
Beta1.40
S&P 52W Chg20.80%
Avg Vol (30d)124.89K
Avg Vol (10d)14.86K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—